Literature DB >> 15076016

Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson Trauma Scale, Clinical Global Impressions and the Clinician-Administered PTSD scale.

Jonathan R T Davidson1.   

Abstract

Rates of remission were examined in two controlled 12-week studies of sertraline and placebo for post-traumatic stress disorder (PTSD). The performance of three scales was evaluated: the self-rated Davidson Trauma Scale (DTS), and two interviewer scales: the Clinician Administered PTSD Scale (CAPS) and Clinical Global Impressions (CGI). Sertraline proved significantly superior to placebo with respect to remission on all three ratings. Rates of remission were very similar for all scales, ranging from 23.1-26.3% for sertraline and 13.9-14.9% for placebo. Traditional thresholds for the CAPS and DTS were tested relative to the CGI and to each other. The CAPS and DTS thresholds of < 20 and < 18 were found to be valid.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15076016     DOI: 10.1097/00004850-200403000-00005

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  9 in total

Review 1.  Treatment of Post-Traumatic Stress Disorders with the Alpha-1 Adrenergic Antagonist Prazosin.

Authors:  Philippe Yves Rémy Simon; Pierre-François Rousseau
Journal:  Can J Psychiatry       Date:  2016-07-19       Impact factor: 4.356

2.  Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment.

Authors:  Kathryn M Connor; Jonathan R T Davidson; Richard H Weisler; Wei Zhang; Kurian Abraham
Journal:  Psychopharmacology (Berl)       Date:  2005-12-10       Impact factor: 4.530

3.  No association between RORA polymorphisms and PTSD in two independent samples.

Authors:  G Guffanti; A E Ashley-Koch; A L Roberts; M E Garrett; N Solovieff; A Ratanatharathorn; I De Vivo; M Dennis; H Ranu; J W Smoller; Y Liu; S M Purcell; J Beckham; M A Hauser; K C Koenen
Journal:  Mol Psychiatry       Date:  2014-07-22       Impact factor: 15.992

4.  A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial.

Authors:  Sanjay J Mathew; Meena Vythilingam; James W Murrough; Carlos A Zarate; Adriana Feder; David A Luckenbaugh; Becky Kinkead; Michael K Parides; David G Trist; Massimo S Bani; Paolo U Bettica; Emiliangelo M Ratti; Dennis S Charney
Journal:  Eur Neuropsychopharmacol       Date:  2010-12-30       Impact factor: 4.600

5.  The Post-Deployment Mental Health (PDMH) study and repository: A multi-site study of US Afghanistan and Iraq era veterans.

Authors:  Mira Brancu; H Ryan Wagner; Rajendra A Morey; Jean C Beckham; Patrick S Calhoun; Larry A Tupler; Christine E Marx; Katherine H Taber; Robin A Hurley; Jared Rowland; Scott D McDonald; Jeffrey M Hoerle; Scott D Moore; Harold S Kudler; Richard D Weiner; John A Fairbank
Journal:  Int J Methods Psychiatr Res       Date:  2017-06-27       Impact factor: 4.035

6.  COMBINED MIRTAZAPINE AND SSRI TREATMENT OF PTSD: A PLACEBO-CONTROLLED TRIAL.

Authors:  Franklin R Schneier; Raphael Campeas; Jaime Carcamo; Andrew Glass; Roberto Lewis-Fernandez; Yuval Neria; Arturo Sanchez-Lacay; Donna Vermes; Melanie M Wall
Journal:  Depress Anxiety       Date:  2015-06-26       Impact factor: 6.505

Review 7.  The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review.

Authors:  A C Parrott
Journal:  Psychopharmacology (Berl)       Date:  2007-02-13       Impact factor: 4.530

Review 8.  Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience.

Authors:  John H Krystal; Alexander Neumeister
Journal:  Brain Res       Date:  2009-03-28       Impact factor: 3.252

9.  Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches.

Authors:  Mathew D Hoskins; Jack Bridges; Robert Sinnerton; Anna Nakamura; Jack F G Underwood; Alan Slater; Matthew R D Lee; Liam Clarke; Catrin Lewis; Neil P Roberts; Jonathan I Bisson
Journal:  Eur J Psychotraumatol       Date:  2021-01-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.